EL
Chief Financial Officer
Get the full picture
Sign in to uncover key details.
Biosceptre
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11 Julius Ave, North Ryde, New South Wal...Phone Number
+44 1223496090Website
www.biosceptre.comRevenue
<$5 MillionIndustry
About Biosceptre
Biosceptre is an innovative company focused on developing targeted therapeutics for cancer patients. They are pioneering a multiple-targeted universal CAR T system, which aims to improve the lives of millions suffering from various malignancies. Their BRiDGECAR system combines nfP2X-targeted CAR T with multiple antibodies, potentially enabling treatment for most cancer types. With several programs targeting both liquid and solid tumors, Biosceptre is dedicated to achieving best-in-class cancer treatments.Explore more
Biosceptre Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Biosceptre
Compare insights from companies similar to Biosceptre, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Biosceptre Tech Stack
A closer look at the technologies used by Biosceptre
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Biosceptre
Sign Up For FreeTo access detailed company insights
Biosceptre is an innovative company focused on developing targeted therapeutics for cancer patients. They are pioneering a multiple-targeted universal CAR T system, which aims to improve the lives of millions suffering from various malignancies. Their BRiDGECAR system combines nfP2X-targeted CAR T with multiple antibodies, potentially enabling trea... Read More
